Microcap Ledger Envoy Medical, Inc. $COCH
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Headquarters
- White Bear Lake, MN
- Fiscal year end
- December 31
- Shares outstanding
- 77,194,595 [10-Q 2026-08-10]
What the company doesAI summary of filing
Envoy Medical develops implantable hearing devices for people with hearing loss. The company's lead product is the Acclaim CI, a fully implanted cochlear implant currently in clinical trials that uses an implanted sensor to detect sound via the ear's natural anatomy rather than external microphones. The Acclaim CI received FDA Breakthrough Device Designation in 2019 and completed enrollment of its 56-patient pivotal clinical trial in March 2025, with FDA approval anticipated in late 2027 or early 2028. The company is pre-revenue from the Acclaim CI; it also markets the Esteem FI-AMEI, an FDA-approved fully implanted active middle ear implant cleared since 2010 but with minimal commercial uptake due to Medicare classification as a hearing aid rather than a cochlear implant. [10-K 2026-03-23]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $90.0K | −$10.33M | −$11.52M | $19.68M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | $241.0K | −$23.76M | −$18.20M | $3.74M | [POS AM 2026-06-12] |
| FY ended Dec 2024 | $225.0K | −$20.80M | −$17.95M | $5.48M | [POS AM 2026-06-12] |
- Quarterly cash burn
- −$5.76M
- Cash runway Estimate
- ~10.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-13 | 20,244,865 | [10-Q 2024-11-14] |
| 2025-03-24 | 21,326,619 | [10-K 2025-03-31] |
| 2025-05-01 | 21,326,619 | [10-Q 2025-05-01] |
| 2025-07-30 | 21,520,932 | [10-Q 2025-07-31] |
| 2025-11-10 | 28,786,511 | [10-Q 2025-11-10] |
| 2026-03-20 | 76,881,110 | [10-K/A 2026-04-13] |
| 2026-05-11 | 76,881,110 | [10-Q 2026-05-11] |
| 2026-08-10 | 77,194,595 | [10-Q 2026-08-10] |
- Shelf registration
- S-1 filed 2025-12-18; declared effective 2026-02-11 [S-1 2025-12-18]
Listing status
Current status: 6 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-05-22. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-05-22 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-05-22] |
| 2026-02-27 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-02-27] |
| 2025-11-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-11-25] |
| 2025-10-28 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-28] |
| 2025-08-29 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-08-29] |
| 2025-03-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-03-03] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-05-29 | Lucas Brent T. | grant | 32,856 | $0.60 | [4 2026-06-04] |
| 2026-02-12 | Patel Mona Chetan | buy | 312,500 | $0.40 | [4 2026-02-17] |
| 2026-02-12 | Potashnick Robert | buy | 212,500 | $0.40 | [4 2026-02-17] |
| 2026-02-12 | Kantor Susan | buy | 96,150 | $0.40 | [4 2026-02-17] |
| 2026-02-12 | Brynelsen Charles | buy | 1,000,000 | $0.40 | [4 2026-02-17] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | 8-K | Other events |
| 2026-09-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-31 | DEF 14A | Proxy statement |
| 2026-08-27 | 8-K | Director or officer change |
| 2026-08-19 | PRE 14A | Proxy statement |
| 2026-08-10 | 8-K | Results of operations |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-06-30 | 8-K | Material agreement terminated |
| 2026-06-25 | 8-K | Director or officer change |
| 2026-05-22 | 8-K | Listing notice or transfer |
| 2026-05-18 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
Alerts for $COCH
Email me when Envoy Medical, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.